A Study of AK104 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status:
Not yet recruiting
Trial end date:
2023-04-08
Target enrollment:
Participant gender:
Summary
This is a phase Ib/II , open-label, multicenter single arm study designed to evaluate the
efficacy, safety, tolerability, pharmacokinetic (PK), and immunogenicity of AK104 combined
with Carboplatin and Pemetrexed/ Paclitaxel as first-line therapy in patients with locally
advanced or metastatic non-small cell lung cancer.